Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease

Frontiers in Pediatrics - Switzerland
doi 10.3389/fped.2020.00146
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Infliximab Pharmacokinetics Are Influenced by Intravenous Immunoglobulin Administration in Patients With Kawasaki Disease

Clinical Pharmacokinetics
Pharmacology
2018English

Predictors and Management of Intravenous Immunoglobulin-Resistant Kawasaki Disease

Korean Journal of Pediatrics
Child HealthPediatricsPerinatology
2019English

Acute and Late Coronary Outcomes in 1073 Patients With Kawasaki Disease With and Without Intravenous Γ-Immunoglobulin Therapy

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
2015English

Parameters to Guide Rescue Therapy for Intravenous Immunoglobulin-Resistant Kawasaki Disease

Journal of Advances in Medicine and Medical Research
2017English

629 Serum Albumin Level Predicts Initial Intravenous Immunoglobulin Treatment Failure in Kawasaki Disease

Pediatric Research
Child HealthPediatricsPerinatology
2010English

Transcriptional Regulation by Infliximab Therapy in Kawasaki Disease Patients With Immunoglobulin Resistance

Pediatric Research
Child HealthPediatricsPerinatology
2014English

Risk Factors of Intravenous Immunoglobulin Resistance and Coronary Arterial Lesions in Turkish Children With Kawasaki Disease

Turkish Journal of Pediatrics
Child HealthPediatricsPerinatology
2020English

A Study of Patients With Kawasaki Disease Who Required an Additional Immunoglobulin Therapy

Pediatric Research
Child HealthPediatricsPerinatology
2003English

Serum Immunoglobulin Trough Levels Following Immunoglobulin Replacement Therapy in Obese and Non-Obese Patients

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy